Skip to content

OBIPHAR: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

OBIPHAR

BE 0878.100.418
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€1,220
2024 · €6,654-€7,874
Equity
€118,848
2024 · €120,068-€1,220
Cash
€118,717
2024 · €115,316+€3,401
Balance sheet total
€218,848
2024 · €120,068+€98,780

Largest movements

2024 to 2025
Assets
  • Intangible fixed assets +€93,333

    new in 2025: €93,333

  • Cash +€3,401

    up €3,401 (+2.9%), from €115,316 to €118,717

    mainly Trade debts (+€100,000) and Depreciation (+€6,667)

Equity and liabilities
  • Trade debts +€100,000

    new in 2025: €100,000

Income statement
  • Depreciation +€6,667

    new in 2025: €6,667

  • Gross operating margin -€3,412

    down €3,412 (-35.0%), from €9,742 to €6,330

  • Taxes -€2,218

    no longer reported in 2025 (was €2,218)

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €6,654
Gross operating margin -€3,412
Depreciation -€6,667
Other operating charges -€13
Taxes +€2,218
Result 2025 -€1,220

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€103,401
Investment -€100,000
Financing €0
Cash 2024 €115,316
Net result for the year -€1,220
Depreciation +€6,667
Receivables within one year -€2,046
Trade debts +€100,000
Investment in fixed assets (net) -€100,000
Cash 2025 €118,717
Every line side by side 30 lines
Line Code 2024 2025 Change %
Total assets 20/58 €120,068 €218,848 +€98,780 +82.3%
Fixed assets 21/28 - €93,333 +€93,333
Intangible fixed assets 21 - €93,333 +€93,333
Current assets 29/58 €120,068 €125,515 +€5,447 +4.5%
Amounts receivable within one year 40/41 €4,752 €6,798 +€2,046 +43.1%
Other amounts receivable 41 €4,752 €6,798 +€2,046 +43.1%
Cash at bank and in hand 54/58 €115,316 €118,717 +€3,401 +2.9%
Total equity and liabilities 10/49 €120,068 €218,848 +€98,780 +82.3%
Equity 10/15 €120,068 €118,848 -€1,220 -1.0%
Contributions 10/11 €100,000 €100,000 = 0.0%
Capital 10 €100,000 €100,000 = 0.0%
Issued capital 100 €100,000 €100,000 = 0.0%
Reserves 13 €4,399 €4,399 = 0.0%
Non-distributable reserves 130/1 €4,399 €4,399 = 0.0%
Legal reserve 130 €4,399 €4,399 = 0.0%
Profit (loss) carried forward 14 €15,669 €14,449 -€1,220 -7.8%
Amounts payable 17/49 - €100,000 +€100,000
Amounts payable within one year 42/48 - €100,000 +€100,000
Trade debts 44 - €100,000 +€100,000
Bills of exchange payable 441 - €100,000 +€100,000
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 - €6,667 +€6,667
Other operating charges 640/8 €387 €400 +€13 +3.4%
Gross operating margin 9900 €9,742 €6,330 -€3,412 -35.0%
Operating profit (loss) 9901 €9,355 -€737 -€10,092
Financial charges 65/66B €483 €483 = 0.0%
Recurring financial charges 65 €483 €483 = 0.0%
Profit (loss) for the period before taxes 9903 €8,872 -€1,220 -€10,092
Income taxes 67/77 €2,218 - -€2,218
Profit (loss) for the period 9904 €6,654 -€1,220 -€7,874
Profit (loss) for the period to be appropriated 9905 €6,654 -€1,220 -€7,874

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.